₹441.40
−6.69%NSE close, 16 Nov 2026
+32.14%
Gufic Biosciences is a small cap company, listed on NSE under the symbol GUFICBIO. At ₹441.40 a share, the market values the whole company at ₹4,426 crore.
In FY26, it reported sales of ₹944 crore and a net profit of ₹64 crore, an operating margin of 16.0%. Over the last three years, sales grew 6.6% a year and net profit fell 12.5% a year.
The market values the company at 55.3 times its profit over the last twelve months and 6.24 times its book value; its return on equity is 11.3% and its borrowings are 0.63 times its equity.
Promoters hold 72.50% of the shares. Foreign institutions hold 0.45%, and domestic institutions, mutual funds among them, 3.38%.
Over the past year the share price has risen 34.5%, and it is 10.6% below its 52-week high.
₹ crore. Consolidated figures.
Link of Recording
Change in Director(s) of the company.
The financial results for the period ended September 30, 2026.
Intimation of Environmental, Social and Governance ( ESG ) Rating
Schedule of meet of Earnings Conference Call scheduled to be held on November 16, 2026
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 202 | 195 | 203 | 204 | 208 | 205 | 224 | 237 | 231 | 252 | 261 | 288 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 165 | 161 | 167 | 166 | 174 | 179 | 190 | 199 | 198 | 205 | 214 | 240 |
| Operating profit | 36.5 | 34.2 | 35.8 | 38.6 | 33.9 | 26.4 | 33.3 | 37.9 | 33.0 | 47.2 | 46.6 | 48.5 |
| Operating margin | 18.1% | 17.6% | 17.6% | 18.9% | 16.3% | 12.9% | 14.9% | 16.0% | 14.3% | 18.7% | 17.9% | 16.8% |
| Other income | 0.4 | 0.9 | 1.3 | 0.1 | 1.9 | 0.4 | 0.9 | 2.1 | 0.8 | −1.2 | 0.5 | 1.1 |
| Interest | 3.2 | 3.7 | 4.6 | 5.2 | 4.9 | 8.4 | 9.2 | 9.6 | 8.4 | 9.4 | 9.3 | 10.4 |
| Depreciation | 4.1 | 4.3 | 4.3 | 4.3 | 4.6 | 7.8 | 7.7 | 7.8 | 7.7 | 7.7 | 7.7 | 7.7 |
| Profit before tax | 29.6 | 27.1 | 28.1 | 29.3 | 26.3 | 10.5 | 17.3 | 22.6 | 17.7 | 29.0 | 30.0 | 31.5 |
| Tax | 7.3 | 7.1 | 7.3 | 7.5 | 7.0 | 2.8 | 4.2 | 5.8 | 5.3 | 7.1 | 7.7 | 8.0 |
| Net profit | 22.3 | 20.1 | 20.9 | 21.8 | 19.3 | 7.7 | 13.1 | 16.8 | 12.4 | 21.9 | 22.3 | 23.5 |
| EPS (₹) | 2.23 | 2.00 | 2.08 | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 | 2.34 |
₹ crore, financial years to March.
| Line | FY20 S | FY21 S | FY22 S | FY23 S | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Sales | 358 | 488 | 779 | 691 | 820 | 944 |
| Expenses | 313 | 404 | 633 | 559 | 685 | 793 |
| Operating profit | 44.6 | 83.9 | 146 | 131 | 135 | 151 |
| Operating margin | 12.5% | 17.2% | 18.7% | 19.0% | 16.4% | 16.0% |
| Other income | 6.8 | 3.7 | 3.1 | 2.6 | 3.6 | 2.7 |
| Interest | 12.7 | 13.6 | 4.9 | 7.6 | 23.1 | 36.6 |
| Depreciation | 8.4 | 16.3 | 17.1 | 19.6 | 21.1 | 30.8 |
| Profit before tax | 30.3 | 57.7 | 127 | 107 | 94.1 | 86.6 |
| Tax | 7.5 | 13.5 | 31.0 | 27.0 | 24.5 | 22.3 |
| Net profit | 22.9 | 44.2 | 95.8 | 79.7 | 69.7 | 64.2 |
| EPS (₹) | 2.94 | 4.56 | 9.89 | 8.23 | 6.95 | 6.40 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 104 | 123 | 45.0 | 5.2 |
| From investing | −95.9 | −70.8 | −31.0 | −42.8 |
| From financing | −3.1 | −37.2 | 32.5 | 40.7 |
| Spent on fixed assets | −88.8 | −75.5 | −31.2 | −36.0 |
| Free cash flow | 15.6 | 47.0 | 13.8 | −30.8 |
Margins, returns, debt, tax and cash.
| Line | FY20 | FY21 | FY22 | FY23 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Net margin | 6.4% | 9.1% | 12.3% | 11.5% | 8.5% | 6.8% |
| Operating margin | 12.5% | 17.2% | 18.7% | 19.0% | 16.4% | 16.0% |
| Return on equity | – | – | – | 22.9% | 11.6% | 9.7% |
| Return on capital employed | – | – | – | 17.3% | 12.9% | 11.7% |
| Return on assets | – | – | – | 9.3% | 6.0% | 4.8% |
| Debt to equity | – | – | – | 0.90 | 0.52 | 0.58 |
| Interest coverage | 3.40 | 5.20 | 27.20 | 15.00 | 5.10 | 3.40 |
| Debt to assets | – | – | – | 0.36 | 0.27 | 0.29 |
| Current ratio | – | – | – | 1.61 | 1.61 | 1.55 |
| Quick ratio | – | – | – | 0.97 | 1.05 | 0.92 |
| Cash ratio | – | – | – | 0.10 | 0.04 | 0.12 |
| Asset turnover | – | – | – | 0.80 | 0.70 | 0.70 |
| Fixed asset turnover | – | – | – | 4.35 | 1.64 | 1.95 |
| Inventory turnover | – | – | – | – | 1.70 | 1.30 |
| Receivables turnover | – | – | – | 3.40 | 2.60 | 3.20 |
| Gross margin | – | – | – | – | 54.3% | 55.4% |
| Cash from operations to profit | – | – | 109.0% | – | 176.0% | 70.0% |
| Effective tax rate | 24.6% | 23.4% | 24.4% | 25.3% | 26.0% | 25.8% |
Intimation regarding USFDA Pre-Approval Inspection at the Company s Manufacturing facility situated at Indore, Madhya Pradesh
The intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of Environmental, Social and Governance ( ESG ) Rating
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
A copy of Scrutinizers report and voting results of 42nd Annual General Meeting held on September 04, 2026
Proceedings of 42nd Annual General Meeting held on September 04, 2026
Promotion and Change in Designation of Senior Management Personnel